Ketamine-like spray being examined as treatment for depression
Esketamine has already been approved in the US and trials show it can relieve symptoms within hours
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Guidance on a drug derived from ketamine which is seen as a potential treatment for depression is undergoing a second public consultation.
Esketamine is applied as a nasal spray to treat severe depression in patients who have not responded well to traditional antidepressants.
The National Institute for Health and Care Excellence (Nice) has launched a second public consultation on its draft guidance which does not recommend the nasal spray medicine for treatment-resistant depression.
Esketamine, also called Spravato, made by Janssen, is being considered by Nice for treating depression in adults who have not responded to at least two different antidepressants.
Evidence from clinical trials suggests esketamine is more effective than placebo but it is unclear how effective it is because of the way the trials were carried out.
The committee concluded that the estimates for esketamine are much higher than what Nice normally considers a cost-effective use of NHS resources.
Nice said a second consultation is required because comments from the first consultation suggested esketamine may be used in the NHS for patients with more severe depression than people in the trials.
Meindert Boysen, deputy chief executive and director of the centre for health technology evaluation at Nice, said: "There is a clear need for effective alternative treatment options for people with treatment-resistant depression.
"Our independent committee very much recognises the priority of addressing mental health challenges for the NHS.
"However, the introduction of esketamine into clinical practice in the NHS will be complex because the structure and delivery of services would need to be changed.
"The committee is not confident that the impact of these changes has been captured adequately, and would like to understand better what the consequences are of patients having repeated courses of esketamine.
"There is also uncertainty about whether improvement in symptoms and quality of life can be sustained and we would like to hear from stakeholders about this."
PA
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments